In high‐risk HPV‐associated cervical cancer, increased expression of PD‐1 and its ligand PD‐L1 is associated with dampened cell‐mediated immunity,26 suggesting that PD‐(L)1 has therapeutic potential in recurrent and/or metastatic CC patients not responding to immunotherapy. This evidence concerns the gene PDCD1 and cervical carcinoma.